pmid stringclasses 42
values | meta_analysis_title stringclasses 42
values | meta_analysis_question stringclasses 42
values | criteria stringclasses 42
values | subgroup stringclasses 242
values | key_reference_title stringclasses 922
values | key_reference_abstract stringclasses 921
values | truth stringclasses 2
values |
|---|---|---|---|---|---|---|---|
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - <30% of pregnant women participating in groups | Effect of a participatory intervention with women's groups on birth outcomes and maternal depression in Jharkhand and Orissa, India: a cluster-randomised controlled trial. | ## BACKGROUND
Community mobilisation through participatory women's groups might improve birth outcomes in poor rural communities. We therefore assessed this approach in a largely tribal and rural population in three districts in eastern India.
## METHODS
From 36 clusters in Jharkhand and Orissa, with an estimated popul... | False |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - <30% of pregnant women participating in groups | Effect of scaling up women's groups on birth outcomes in three rural districts in Bangladesh: a cluster-randomised controlled trial. | ## BACKGROUND
Two recent trials have shown that women's groups can reduce neonatal mortality in poor communities. We assessed the effectiveness of a scaled-up development programme with women's groups to address maternal and neonatal care in three rural districts of Bangladesh.
## METHODS
18 clusters (with a mean popul... | True |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - <30% of pregnant women participating in groups | Community mobilization in Mumbai slums to improve perinatal care and outcomes: a cluster randomized controlled trial. | ## INTRODUCTION
Improving maternal and newborn health in low-income settings requires both health service and community action. Previous community initiatives have been predominantly rural, but India is urbanizing. While working to improve health service quality, we tested an intervention in which urban slum-dweller wo... | True |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - <30% of pregnant women participating in groups | Effect of women's groups and volunteer peer counselling on rates of mortality, morbidity, and health behaviours in mothers and children in rural Malawi (MaiMwana): a factorial, cluster-randomised controlled trial. | ## BACKGROUND
Women's groups and health education by peer counsellors can improve the health of mothers and children. We assessed their effects on mortality and breastfeeding rates in rural Malawi.
## METHODS
We did a 2×2 factorial, cluster-randomised trial in 185,888 people in Mchinji district. 48 equal-sized clusters... | False |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - <30% of pregnant women participating in groups | Effects of quality improvement in health facilities and community mobilization through women's groups on maternal, neonatal and perinatal mortality in three districts of Malawi: MaiKhanda, a cluster randomized controlled effectiveness trial. | ## BACKGROUND
Maternal, perinatal and neonatal mortality remains high in low-income countries. We evaluated community and facility-based interventions to reduce deaths in three districts of Malawi.
## METHODS
We evaluated a rural participatory women's group community intervention (CI) and a quality improvement interven... | True |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - <30% of pregnant women participating in groups | The effect of increased coverage of participatory women's groups on neonatal mortality in Bangladesh: A cluster randomized trial. | ## IMPORTANCE
Community-based interventions can reduce neonatal mortality when health systems are weak. Population coverage of target groups may be an important determinant of their effect on behavior and mortality. A women's group trial at coverage of 1 group per 1414 population in rural Bangladesh showed no effect on... | False |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | Effect of a participatory intervention with women's groups on birth outcomes in Nepal: cluster-randomised controlled trial. | ## BACKGROUND
Neonatal deaths in developing countries make the largest contribution to global mortality in children younger than 5 years. 90% of deliveries in the poorest quintile of households happen at home. We postulated that a community-based participatory intervention could significantly reduce neonatal mortality ... | True |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | Effect of a participatory intervention with women's groups on birth outcomes and maternal depression in Jharkhand and Orissa, India: a cluster-randomised controlled trial. | ## BACKGROUND
Community mobilisation through participatory women's groups might improve birth outcomes in poor rural communities. We therefore assessed this approach in a largely tribal and rural population in three districts in eastern India.
## METHODS
From 36 clusters in Jharkhand and Orissa, with an estimated popul... | True |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | Effect of scaling up women's groups on birth outcomes in three rural districts in Bangladesh: a cluster-randomised controlled trial. | ## BACKGROUND
Two recent trials have shown that women's groups can reduce neonatal mortality in poor communities. We assessed the effectiveness of a scaled-up development programme with women's groups to address maternal and neonatal care in three rural districts of Bangladesh.
## METHODS
18 clusters (with a mean popul... | False |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | Community mobilization in Mumbai slums to improve perinatal care and outcomes: a cluster randomized controlled trial. | ## INTRODUCTION
Improving maternal and newborn health in low-income settings requires both health service and community action. Previous community initiatives have been predominantly rural, but India is urbanizing. While working to improve health service quality, we tested an intervention in which urban slum-dweller wo... | False |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | Effect of women's groups and volunteer peer counselling on rates of mortality, morbidity, and health behaviours in mothers and children in rural Malawi (MaiMwana): a factorial, cluster-randomised controlled trial. | ## BACKGROUND
Women's groups and health education by peer counsellors can improve the health of mothers and children. We assessed their effects on mortality and breastfeeding rates in rural Malawi.
## METHODS
We did a 2×2 factorial, cluster-randomised trial in 185,888 people in Mchinji district. 48 equal-sized clusters... | True |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | Effects of quality improvement in health facilities and community mobilization through women's groups on maternal, neonatal and perinatal mortality in three districts of Malawi: MaiKhanda, a cluster randomized controlled effectiveness trial. | ## BACKGROUND
Maternal, perinatal and neonatal mortality remains high in low-income countries. We evaluated community and facility-based interventions to reduce deaths in three districts of Malawi.
## METHODS
We evaluated a rural participatory women's group community intervention (CI) and a quality improvement interven... | False |
23683640 | Women's groups practising participatory learning and action to improve maternal and newborn health in low-resource settings: a systematic review and meta-analysis. | What are the effects of women's groups practising participatory learning and action on maternal and neonatal health outcomes in low-resource settings compared to usual care? | No criteria | Subgroup analysis of the effect of women’s groups on maternal mortality (A) and neonatal mortality (B), by percentage of pregnant women participating in groups - >30% of pregnant women participating in groups | The effect of increased coverage of participatory women's groups on neonatal mortality in Bangladesh: A cluster randomized trial. | ## IMPORTANCE
Community-based interventions can reduce neonatal mortality when health systems are weak. Population coverage of target groups may be an important determinant of their effect on behavior and mortality. A women's group trial at coverage of 1 group per 1414 population in rural Bangladesh showed no effect on... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. | ## PURPOSE
Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.
## MATERIAL AND METHODS
We updated our institutional outcomes with a neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis w... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. | ## BACKGROUND
Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant toxicity.
## MATERIALS AND METHODS
A retrospective review was performed of all patients with locally advanced or metastatic PDA treated wit... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. | ## CONTEXT
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
## OBJECTIVE
The purpose of this study was to examine the tolerance and effectiveness of FOLFIRINOX as practiced outside of the confines of a clinical trial a... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Neutropenia | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. | ## BACKGROUND
Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FO... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. | ## PURPOSE
Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.
## MATERIAL AND METHODS
We updated our institutional outcomes with a neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis w... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. | ## BACKGROUND
Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant toxicity.
## MATERIALS AND METHODS
A retrospective review was performed of all patients with locally advanced or metastatic PDA treated wit... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. | ## CONTEXT
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
## OBJECTIVE
The purpose of this study was to examine the tolerance and effectiveness of FOLFIRINOX as practiced outside of the confines of a clinical trial a... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Thrombocytopenia | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. | ## BACKGROUND
Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FO... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. | ## PURPOSE
Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.
## MATERIAL AND METHODS
We updated our institutional outcomes with a neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis w... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. | ## BACKGROUND
Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant toxicity.
## MATERIALS AND METHODS
A retrospective review was performed of all patients with locally advanced or metastatic PDA treated wit... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. | ## CONTEXT
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
## OBJECTIVE
The purpose of this study was to examine the tolerance and effectiveness of FOLFIRINOX as practiced outside of the confines of a clinical trial a... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Fatigue | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. | ## BACKGROUND
Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FO... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. | ## PURPOSE
Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.
## MATERIAL AND METHODS
We updated our institutional outcomes with a neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis w... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. | ## BACKGROUND
Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant toxicity.
## MATERIALS AND METHODS
A retrospective review was performed of all patients with locally advanced or metastatic PDA treated wit... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. | ## CONTEXT
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
## OBJECTIVE
The purpose of this study was to examine the tolerance and effectiveness of FOLFIRINOX as practiced outside of the confines of a clinical trial a... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Vomiting | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. | ## BACKGROUND
Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FO... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. | ## PURPOSE
Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.
## MATERIAL AND METHODS
We updated our institutional outcomes with a neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis w... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. | ## BACKGROUND
Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant toxicity.
## MATERIALS AND METHODS
A retrospective review was performed of all patients with locally advanced or metastatic PDA treated wit... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. | ## CONTEXT
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
## OBJECTIVE
The purpose of this study was to examine the tolerance and effectiveness of FOLFIRINOX as practiced outside of the confines of a clinical trial a... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of reported grade 3 or 4 adverse event rates - Diarrhoea | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. | ## BACKGROUND
Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FO... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. | ## PURPOSE
Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer.
## MATERIAL AND METHODS
We updated our institutional outcomes with a neoadjuvant chemotherapy and stereotactic body radiotherapy (SBRT) approach. An IRB-approved analysis w... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. | ## BACKGROUND
Pancreatic ductal adenocarcinoma (PDA) has a very poor prognosis. Treatment with FOLFIRINOX has been shown to improve outcomes, but can be associated with significant toxicity.
## MATERIALS AND METHODS
A retrospective review was performed of all patients with locally advanced or metastatic PDA treated wit... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. | ## CONTEXT
Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
## OBJECTIVE
The purpose of this study was to examine the tolerance and effectiveness of FOLFIRINOX as practiced outside of the confines of a clinical trial a... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Resection | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. | ## BACKGROUND
Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FO... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. | ## BACKGROUND
Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.
## METHODS
Retrospective review of outcomes of patients with borderline resectable o... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. | ## PURPOSE
To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA).
## PATIENTS AND METHODS
Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folf... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. | The objective of our retrospective institutional experience is to report the overall response rate, R0 resection rate, progression-free survival, and safety/toxicity of neoadjuvant FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and chemoradiation in patients with locally advanced pancreatic... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. | ## PURPOSE
On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopa... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. | Although FOLFIRINOX significantly increases survival in metastatic pancreatic cancer (MPC) compared to gemcitabine (Conroy et al. N Engl J Med 364:1817-1825, 2011), toxicities have tempered enthusiasm for its use in full doses. To assess the impact of dose attenuations on toxicity and efficacy, we reviewed our institut... | False |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. | FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively analyzed 49 patients with unresectable pancreatic cancer treated with ... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. | ## BACKGROUND
5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC).
## METHODS
In this retrosp... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. | ## OBJECTIVES
FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, and irinotecan) as compared with gemcitabine in pancreatic cancer (PC) has superior activity and increased toxicity. The bolus 5-FU contributes to the toxicity. We hypothesized that the elimination of bolus 5-FU and use of hematopoietic growth factor will im... | True |
27160474 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. | Is FOLFIRINOX an effective first-line treatment for patients with locally advanced pancreatic cancer, and what are its impacts on overall survival, progression-free survival, and treatment-related adverse events? | Eligible studies included treatment naïve patients of any age who received FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intraveno... | Forest plots of the percentage of (chemo)radiation, resection, and R0 resection - Radiotherapy or chemoradiotherapy | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. | ## BACKGROUND
First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine. The aim of this observational cohort was to evaluate the tolerability and efficacy of this regimen in unresectable locally advanced PA (L... | True |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.